

## Overview

### Useful For

As a marker of severe combined immunodeficiency (SCID)

### Method Name

Kinetic Spectrophotometry

### NY State Available

No

## Specimen

### Specimen Type

Whole Blood EDTA

### Specimen Required

**Container/Tube:** Lavender top (EDTA), pink top (K2 EDTA), or green top (sodium or lithium heparin)

**Specimen Volume:** 1 mL

**Collection Instructions:** Send 1 mL whole blood refrigerate.

### Specimen Minimum Volume

0.5 mL

### Reject Due To

Hemolysis	Reject
-----------	--------

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Whole Blood EDTA	Refrigerated (preferred)	15 days	
	Ambient	15 days	

## Clinical & Interpretive

### Clinical Information

Adenosine deaminase (ADA) deficiency is an autosomal recessive disorder of purine metabolism primarily affecting lymphocyte development, viability, and function. Lack of ADA allows deoxyadenosine to accumulate and kill lymphocytes.

**Reference Values**

400 - 900 mU/g Hb

**Interpretation**

Affected individuals have less than 1% of normal adenosine deaminase (ADA) catalytic activity in red cell hemolysates. ADA deficiency is the cause of 20% to 30% of severe combined immunodeficiency (SCID) cases. Heterozygotes cannot be identified by this test.

**Cautions**

If the patient has been recently transfused, adenosine deaminase (ADA) deficiency may be masked; interpret results with caution.

**Performance****PDF Report**

No

**Day(s) Performed**

Sunday, Tuesday, Thursday

**Report Available**

3 to 8 days

**Performing Laboratory Location**

ARUP Laboratories

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

**CPT Code Information**

84311

---

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
FADBC	Adenosine Deaminase RBC	47549-1

Result ID	Test Result Name	Result LOINC® Value
FADBC	Adenosine Deaminase RBC	47549-1